Small study aims to perfect bleeding drug dose for joint replacements

NCT ID NCT05075200

Completed Knowledge-focused Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial studied how the drug tranexamic acid (TXA) is processed in the body during hip or knee replacement surgery. 21 adults received a standard dose of TXA, and researchers measured drug levels in the blood to build a model for optimal dosing. The goal is to reduce blood loss and the need for transfusions after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tranexamic acid
What this could lead to: If successful, this could lead to better dosing guidelines for tranexamic acid during joint replacement surgery, helping reduce blood loss and the need for transfusions.
What could go wrong: This was a small, early-phase study with only 21 participants, so results may not apply to all patients. The focus was on drug levels in the blood, not on direct patient outcomes like reduced transfusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHROPLASTY REPLACEMENT, KNEE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHROPLASTY REPLACEMENT, KNEE ARTHROPLASTY, REPLACEMENT, HIP

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.